A composition of a medicinal and edible extract and application thereof in improving hyperuricemia

Abstract

The present application belongs to the field of natural medicine and food technology, and discloses a kind of composition of medicinal and edible extract, the composition of medicinal and edible extract is prepared from medlar, hawthorn, mint, waxgourd peel and baizhi.The present application selects medlar, hawthorn, mint, waxgourd peel and baizhi according to the medicinal and edible traditional Chinese medicine catalogue issued by the health commission, extracts and scientifically compound, provides a kind of composition of medicinal and edible extract capable of reducing uric acid, which has the characteristics of simple prescription, obvious curative effect, no toxic side effects.

Description

Technical Field

[0001] This invention belongs to the field of natural medicine and food technology, and in particular to a composition of a medicinal and edible extract and its application in improving hyperuricemia. Background Technology

[0002] Hyperuricemia refers to a serum urate concentration exceeding the solubility limit (approximately 6.8 mg / L), and is a common biochemical abnormality reflecting extracellular fluid supersaturation. It is mainly caused by excessive uric acid secretion or insufficient renal uric acid excretion. Both excessive secretion and insufficient excretion disrupt serum uric acid homeostasis. Internationally, the diagnostic criteria for hyperuricemia are defined as: under normal dietary conditions, two separate fasting serum uric acid levels exceeding 420 μmol / L for men and 360 μmol / L for women. In recent years, the incidence of hyperuricemia has increased significantly, with men typically experiencing a higher incidence than women, and the affected population is trending younger. Patients with hyperuricemia are more prone to gout and are also more likely to have complications such as chronic kidney disease, obesity, diabetes, and hypertension. Hyperuricemia poses a serious threat to human health and quality of life, increasing the public health burden on society. Modern medicine believes that hyperuricemia is mostly caused by consuming large amounts of high-purine, high-protein, or high-fructose foods and drinks, leading to purine metabolism disorders and an imbalance in the level of uric acid, the end product of purine metabolism. This uric acid accumulates in the blood, and its elevated levels cause a series of adverse reactions and damage to multiple organs, including the kidneys. Lifestyle and dietary interventions are often insufficient to effectively control uric acid levels. Most uric acid-lowering drugs have side effects, and long-term use is often intolerable to patients. Therefore, there is an urgent need for effective treatments with minimal side effects in the clinical treatment of hyperuricemia. Searching for natural compounds with strong uric acid-lowering activity and kidney-protective effects that are highly efficient, safe, and non-toxic to lower uric acid is gradually becoming a new direction in research on improving hyperuricemia.

[0003] According to the "Regulations on the Management of Substances That Are Traditionally Both Food and Traditional Chinese Medicine" issued by the National Health Commission, food-medicine substances refer to substances that are traditionally used as food and are listed in the "Pharmacopoeia of the People's Republic of China." Therefore, substances that are both food and medicine are essentially substances that are safe for long-term consumption with no (or very low) side effects and also have efficacy. Thus, substances that are both food and medicine can be taken long-term at prescribed dosages and are relatively safe for the human body. They can also be used as dietary ingredients and have advantages such as safety, few toxic side effects, stable efficacy, and economy in improving hyperuricemia. For the treatment of hyperuricemia, they compensate for the shortcomings of Western medicine, such as the inability to be taken for a long time and the large side effects. Existing studies have demonstrated that gardenia, poria cocos, chicory, dandelion, mulberry leaf, kudzu root, purslane, and lily have uric acid-lowering functions. Currently, most uric acid-lowering products in China add chicory, poria cocos, and coix seed, which are both food and medicine, resulting in similar formulas and severe homogenization. There is still much room for research into using food and medicine as raw materials to improve hyperuricemia. For example, peppermint, wolfberry, hawthorn, angelica dahurica, and winter melon peel are common food and medicine ingredients in daily life. Peppermint, the whole herb or leaves of the mint plant (Lamiaceae family), is used medicinally and has a pungent and cooling nature. Goji berries enter the lung and liver meridians, and have the effects of dispersing wind-heat, clearing the head and eyes, relieving sore throat and promoting rash eruption, and soothing the liver and regulating qi. Goji berries originated in China and are a nutritious and health-promoting vegetable and a precious traditional Chinese medicine. The *Shennong Bencao Jing* records: "Goji berries treat internal evil qi, thirst due to heat, and rheumatism. Long-term consumption strengthens tendons and bones, promotes longevity, and improves resistance to cold and heat." Goji berries are sweet and neutral in nature, and have the effects of nourishing the liver, kidneys, and lungs. Hawthorn berries are sour and sweet, slightly warm in nature, and enter the spleen, stomach, and liver meridians. Books such as *Bencao Tujing* and *Bencao Zaixin* record the effects of hawthorn berries. It has the effects of promoting digestion and strengthening the stomach, regulating qi and dispersing blood stasis. It can also treat diarrhea and abdominal pain, amenorrhea due to blood stasis, postpartum blood stasis, stabbing pain in the heart and abdomen, hernia pain, and hyperlipidemia. Angelica dahurica is pungent and warm in nature, and enters the lung, spleen, and stomach meridians. It has the effects of relieving exterior syndromes and dispersing cold, dispelling wind and relieving pain, clearing nasal passages, drying dampness and stopping leukorrhea, reducing swelling and draining pus, and dispelling wind and relieving itching. It can inhibit the activity of tyrosinase, prevent the production of melanin, whiten skin, treat freckles, and has anti-tumor and liver-protecting effects. Winter melon peel is the dried outer pericarp of winter melon, a plant of the Cucurbitaceae family. It is sweet and cool in nature and enters the body. The spleen and small intestine meridians have diuretic and swelling-reducing effects. The above five medicinal and edible ingredients can be used in daily life for soaking in water for cooking or infusing in alcohol as medicinal cuisine or medicinal wine. Medicinal and edible ingredients have the advantages of multiple targets and pathways. The selected medicinal and edible ingredients belong to different meridians, but the effects of their extracts on improving hyperuricemia have not been reported. Whether the combination has a better uric acid-lowering effect is unclear. If such substances can be used as a base formula to develop foods or beverages that can improve hyperuricemia, it would be of great significance. Based on this, this invention evaluates the function of a combination of the five medicinal and edible extracts, which can effectively lower blood uric acid and improve hyperuricemia. Summary of the Invention

[0004] The purpose of this invention is to overcome the shortcomings of the prior art and provide a composition of medicinal and edible extracts and its application in improving hyperuricemia.

[0005] The technical solution adopted by this invention to solve its technical problem is:

[0006] A composition of a medicinal and edible extract, wherein the composition of the medicinal and edible extract is prepared from wolfberry, hawthorn, peppermint, winter melon peel and angelica dahurica.

[0007] Furthermore, the medicinal and edible extract composition has the ability to reduce serum uric acid and serum creatinine levels in hyperuricemia model animals, affect the expression levels of serum adenosine deaminase and xanthine oxidase, improve liver and kidney damage, and improve hyperuricemia.

[0008] Furthermore, extracts of the wolfberry, hawthorn, peppermint, winter melon peel, and angelica dahurica are prepared and scientifically compounded into a medicinal and edible homologous extract composition.

[0009] Furthermore, the preparation method of the medicinal and edible homologous extract is as follows: each raw material is pulverized and passed through a 100-mesh sieve, added to distilled water at a mass ratio of 1:20, decocted for 1 hour, filtered through double-layer gauze, and the solvent distilled water is added to the original weight. This process is repeated three times to obtain a liquid extract, which is then concentrated by rotary evaporation at 60°C in a water bath and 4°C in condensed water for 2 hours. Finally, it is freeze-dried under vacuum to obtain freeze-dried powder of each medicinal and edible homologous extract.

[0010] Furthermore, the composition of the medicinal and edible extracts comprises wolfberry extract, hawthorn extract, angelica dahurica extract, peppermint extract, and winter melon peel extract, with the following weight proportions of each ingredient:

[0011] The total weight of the five ingredients is 100 parts: 10-30 parts of wolfberry extract, 1-10 parts of hawthorn extract, 1-10 parts of angelica dahurica extract, 30-60 parts of peppermint extract, and 30-60 parts of winter melon peel extract.

[0012] Mix the above five extracts to obtain a composition of medicinal and edible extracts.

[0013] Furthermore, the composition of the medicinal and edible extracts has the ability to reduce serum uric acid and improve hyperuricemia in hyperuricemia model animals;

[0014] Alternatively, the composition of the medicinal and edible extracts can reduce serum uric acid and creatinine levels in hyperuricemia model mice;

[0015] Alternatively, the composition of the medicinal and edible extracts can effectively alleviate liver and kidney damage in hyperuricemia model mice and has a certain liver and kidney protection effect.

[0016] Alternatively, the medicinal and edible extract composition can reduce serum uric acid and serum creatinine levels in hyperuricemia model animals, affect the expression levels of serum adenosine deaminase and xanthine oxidase, and improve hyperuricemia.

[0017] The use of the composition of the medicinal and edible extracts as described above in the preparation of medicines for relieving hyperuricemia and / or lowering uric acid.

[0018] Furthermore, the composition of the medicinal and edible extracts in the medicine is in the form of a solid or liquid;

[0019] Alternatively, the medicine may include a pharmaceutically acceptable carrier;

[0020] Alternatively, the product being developed may be in any form of pharmaceutical.

[0021] Furthermore, the dosage form of the drug includes one or more oral preparations selected from tablets, capsules, oral liquids, or lyophilized preparations.

[0022] The advantages and positive effects of this invention are as follows:

[0023] 1. Based on the list of medicinal and edible herbs published by the National Health Commission, this invention selects wolfberry, hawthorn, mint, winter melon peel and angelica dahurica for extraction and scientific compounding, and provides a composition of medicinal and edible extracts that can lower uric acid. It has the characteristics of simple formulation, obvious curative effect and no toxic side effects.

[0024] 2. This invention establishes a hyperuricemia model in mice by intraperitoneal injection of potassium oxonate supplemented with a high-purine diet. After 21 days of successful modeling, the mice in the group with the medicinal and edible extract composition showed significantly reduced serum uric acid and serum creatinine levels, and changes in the expression levels of serum adenosine deaminase and xanthine oxidase, demonstrating the ability to improve hyperuricemia. This proves that the medicinal and edible extract composition of this invention helps improve hyperuricemia, and therefore it can be used as a novel measure to alleviate hyperuricemia, with broad application prospects in the adjuvant treatment of hyperuricemia.

[0025] 3. The efficacy of this invention has been confirmed through animal experiments. The results of the animal experiments show that the medicinal and edible extract composition of this invention has the effects of lowering uric acid and protecting liver and kidney function.

[0026] 4. The food-medicine homologous extract composition of the present invention can reduce the serum uric acid level in hyperuricemia model mice. It is a food-medicine homologous composition with uric acid-lowering effect and can be used in drugs to relieve hyperuricemia.

[0027] 5. The medicinal and edible extract composition of the present invention can alleviate liver and kidney damage in mice with high uric acid, and has the effect of protecting the liver and kidneys.

[0028] 6. The food-medicine homology extract composition of the present invention has excellent uric acid lowering ability. This composition is readily available, has few side effects, and has a strong uric acid lowering ability.

[0029] 7. The purpose of this invention is to overcome the problems of poor efficacy, side effects, and slow onset of action of uric acid-lowering drugs, and to provide a composition of medicinal and edible extracts with uric acid-lowering function, its preparation method, and its application. By compounding extracts with good uric acid-lowering effects, the efficacy is enhanced, the loss of active pharmaceutical ingredients is reduced, and thus a better uric acid-lowering effect is achieved. Furthermore, the uric acid-lowering medicinal and edible extract composition of this invention is simple to prepare, uses inexpensive raw materials, is easy to prepare, and is convenient to consume, possessing advantages of low cost and ease of application, and has broad application prospects. Attached Figure Description

[0030] Figure 1 This is a graph showing the effect of the traditional Chinese medicine and food homology extract composition of the present invention on the body weight of mice with hyperuricemia;

[0031] Figure 2 This is a graph showing the effect of the traditional Chinese medicine and food homology extract composition of the present invention on serum uric acid in hyperuricemic mice;

[0032] Figure 3 The figure shows the effect of the traditional Chinese medicine and food homology extract composition of this invention on serum creatinine in mice with hyperuricemia.

[0033] Figure 4 This is a graph showing the effect of the traditional Chinese medicine and food homology extract composition of the present invention on serum adenosine deaminase in hyperuricemic mice;

[0034] Figure 5 This is a graph showing the effect of the traditional Chinese medicine and food homology extract composition of the present invention on serum xanthine oxidase in hyperuricemic mice;

[0035] Figure 6 This figure shows the effects of the traditional Chinese medicine and food homology extract composition of this invention on the liver and kidneys of mice with hyperuricemia. Detailed Implementation

[0036] The present invention will be further described below with reference to the embodiments. The following embodiments are descriptive and not limiting, and should not be used to limit the scope of protection of the present invention.

[0037] The various experimental operations involved in the specific embodiments are all conventional techniques in the field. For parts not specifically annotated in this document, those skilled in the art can refer to various commonly used reference books, scientific and technological documents or related instructions and manuals prior to the filing date of this invention to carry out the operations.

[0038] A composition of a medicinal and edible extract, wherein the composition of the medicinal and edible extract is prepared from wolfberry, hawthorn, peppermint, winter melon peel and angelica dahurica.

[0039] Preferably, the medicinal and edible extract composition has the ability to reduce serum uric acid and serum creatinine levels in hyperuricemia model animals, affect the expression levels of serum adenosine deaminase and xanthine oxidase, improve liver and kidney damage, and improve hyperuricemia.

[0040] Preferably, the wolfberry, hawthorn, peppermint, winter melon peel and angelica dahurica are each used to prepare extracts, and then scientifically compounded into a medicinal and edible extract composition.

[0041] Preferably, the preparation method of the medicinal and edible extracts is as follows: each raw material is pulverized and passed through a 100-mesh sieve, distilled water is added at a mass ratio of 1:20, decocted for 1 hour, filtered through double-layer gauze, and distilled water is added to the original weight. This process is repeated three times to obtain a liquid extract, which is then concentrated by rotary evaporation at 60°C in a water bath and 4°C in condensate for 2 hours. Finally, it is freeze-dried under vacuum to obtain freeze-dried powder of each medicinal and edible extract.

[0042] Preferably, the composition of the medicinal and edible extracts comprises wolfberry extract, hawthorn extract, angelica dahurica extract, peppermint extract, and winter melon peel extract, with the following weight parts for each ingredient:

[0043] The total weight of the five ingredients is 100 parts: 10-30 parts of wolfberry extract, 1-10 parts of hawthorn extract, 1-10 parts of angelica dahurica extract, 30-60 parts of peppermint extract, and 30-60 parts of winter melon peel extract.

[0044] Mix the above five extracts to obtain a composition of medicinal and edible extracts.

[0045] Preferably, the composition of the medicinal and edible extracts has the ability to reduce serum uric acid and improve hyperuricemia in animals with hyperuricemia.

[0046] Alternatively, the composition of the medicinal and edible extracts can reduce serum uric acid and creatinine levels in hyperuricemia model mice;

[0047] Alternatively, the composition of the medicinal and edible extracts can effectively alleviate liver and kidney damage in hyperuricemia model mice and has a certain liver and kidney protection effect.

[0048] Alternatively, the medicinal and edible extract composition can reduce serum uric acid and serum creatinine levels in hyperuricemia model animals, affect the expression levels of serum adenosine deaminase and xanthine oxidase, and improve hyperuricemia.

[0049] The use of the composition of the medicinal and edible extracts as described above in the preparation of medicines for relieving hyperuricemia and / or lowering uric acid.

[0050] Preferably, the composition of the medicinal and edible extracts in the medicine is a solid or a liquid;

[0051] Alternatively, the medicine may include a pharmaceutically acceptable carrier;

[0052] Alternatively, the product being developed may be in any form of pharmaceutical.

[0053] Preferably, the dosage form of the drug includes one or more oral preparations selected from tablets, capsules, oral liquids or lyophilized preparations.

[0054] Specifically, the following examples illustrate the technical solution of the present invention through the preparation of the food-medicine homology extract composition and its effect on improving hyperuricemia in animals. Specifically, the relevant preparation and testing are as follows:

[0055] Based on international diagnostic criteria for hyperuricemia, this invention proposes to use changes in blood uric acid levels as the selection criterion for screening five medicinal and edible extracts.

[0056] Example 1: Preparation of a medicinal and edible extract composition:

[0057] The preparation of the medicinal and edible homologous extracts is as follows: each raw material is pulverized and passed through a 100-mesh sieve, and distilled water is added at a mass ratio of 1:20. The mixture is decocted for 1 hour, filtered through double-layer gauze, and distilled water is added to the original weight. This process is repeated three times to obtain a liquid extract. The extract is then concentrated by rotary evaporation at 60°C in a water bath and 4°C in condensate for 2 hours. After vacuum freeze-drying, the freeze-dried powders of each medicinal and edible homologous extract are obtained and redissolved in physiological saline.

[0058] The medicinal and edible combination is made from the following components in parts by weight: 10-30 parts of wolfberry extract, 1-10 parts of hawthorn extract, 1-10 parts of angelica dahurica extract, 30-60 parts of peppermint extract, and 30-60 parts of winter melon peel extract, with the sum of the parts by weight of these five raw materials being 100 parts. Details are as follows:

[0059] Example 1

[0060] The preferred ingredients are 20 parts of wolfberry extract, 5 parts of hawthorn extract, 5 parts of angelica extract, 40 parts of peppermint extract, and 30 parts of winter melon peel extract.

[0061] Example 2

[0062] 10 parts of wolfberry extract, 10 parts of hawthorn extract, 10 parts of angelica extract, 30 parts of peppermint extract, and 40 parts of winter melon peel extract.

[0063] Example 3

[0064] 30 parts of wolfberry extract, 8 parts of hawthorn extract, 12 parts of angelica dahurica extract, 25 parts of peppermint extract, and 25 parts of winter melon peel extract.

[0065] Example 2: Application of the medicinal and edible extract composition in improving hyperuricemia:

[0066] The composition of the medicinal and edible extracts used in the relevant tests is the composition of the medicinal and edible extracts prepared in Example 1 above.

[0067] A mouse model of hyperuricemia was established by intraperitoneal injection of potassium oxonate supplemented with a high-purine diet. Fifty SPF male Kunming mice were used, housed at room temperature with free access to food. After 7 days of acclimatization, they were randomly divided into four groups (n=10 per group): a normal control group (NC), a hyperuricemia model group (M), an allopurinol (AP) treatment group, a low-dose treatment group (200 mg / kg*d) of a food-derived medicinal compound (ML), and a high-dose treatment group (600 mg / kg*d) of the same compound (MH). Except for the normal control group, the other four groups of mice received intraperitoneal injections of potassium oxonate at a standard dose of 300 mg / kg*d and were administered standard yeast extract by gavage at a dose of 10 g / kg*d to induce the hyperuricemia model. In addition, the normal control group and the hyperuricemia model group were administered physiological saline by gavage; the AP group mice were administered allopurinol by gavage at a standard of 30 mg / kg*d for 21 days. Before the last administration, the mice were fasted but allowed to drink water. After the last administration, the mice had their eyes removed and blood was collected. The serum was used for the determination of indicators. After blood collection, the mice were euthanized by dislocation and the liver and kidney tissues were dissected for H&E staining and sectioning.

[0068] Hyperuricemia is a metabolic disease. While a high-purine diet can induce hyperuricemia, it can also cause complications such as obesity. Uric acid (UA) is the end product of purine metabolism, and UA measurement is a biochemical marker for diagnosing hyperuricemia caused by purine metabolism. Creatinine (CRE) is an important clinical indicator for evaluating renal function impairment. Two key enzymes involved in UA synthesis are xanthine oxidase (XOD) and adenosine deaminase (ADA). Increased XOD expression leads to increased uric acid levels; ADA activity is a sensitive indicator of liver damage. Experimental data show that after 21 days of continuous intraperitoneal injection of potassium oxonate combined with a high-purine diet, [the following text appears to be incomplete and requires further context: "by..."] Figure 1 The mice in group M showed the fastest weight gain, generally higher than other groups, which is related to the obesity induced by a high-purine diet and hyperuricemia. Mice in group AP showed the slowest weight gain and lower weight than other groups, while the treatment groups ML and MH were closer to the normal weight. This indicates that the positive control drug allopurinol affects mouse growth, and both high and low doses of the drug-food homology extract combination can normalize the growth of hyperuricemia model mice. Figure 2The serum uric acid level in group M mice was significantly higher than that in the normal NC group, increasing from 71.38 μmol / L to 136.6 μmol / L. However, after intervention in the treatment group ML and the high-dose group MH, the serum uric acid level in the ML group decreased to 81.06 μmol / L, and the serum uric acid level in the MH group decreased to 84.03 μmol / L, significantly lower than that in group M mice and approaching the serum uric acid level in the NC group. This indicates that both low and high doses of the combination of food-derived medicinal extracts have the effect of reducing serum uric acid in mice. Creatinine and uric acid are both indicators of kidney function. Creatinine is a more accurate predictor of kidney function; elevated creatinine suggests a decreased kidney detoxification capacity. High serum uric acid and creatinine levels generally indicate possible renal insufficiency accompanied by hyperuricemia. Figure 3 As shown, serum creatinine levels increased in both the M and AP groups, while serum creatinine levels decreased in the treatment groups ML and MH, with the low-dose combination of medicinal and food-derived ingredients showing better effects. Uric acid formation in the body is related to two enzymes: adenosine deaminase (ADA) and xanthine oxidase (XOD). These two enzymes are key enzymes catalyzing and regulating uric acid production. ADA catalyzes the conversion of adenosine to inosine, which further produces hypoxanthine and xanthine, indirectly catalyzing uric acid formation. XOD directly catalyzes the gradual oxidation of hypoxanthine and xanthine to form uric acid, and also converts dietary proteins into purines, ultimately forming uric acid. Figure 4 As shown, the ADA activity in groups M and AP was significantly higher than that in group NC. However, after intervention, the ADA activity in both groups ML and MH decreased, with the ML group showing the most significant reduction. Figure 5 It was found that the XOD activity in the blood of mice in group M was increased, while that in mice in group AP was decreased. Pharmacologically, allopurinol is an isomer of hypoxanthine. Hypoxanthine and xanthine can be catalyzed by xanthine oxidase to produce uric acid, and allopurinol is also catalyzed by xanthine oxidase to convert to alloxanthine; both allopurinol and alloxanthine can inhibit xanthine oxidase. Therefore, under the action of allopurinol, uric acid production and excretion are reduced, preventing the deposition of urate microcrystals. The XOD activity in group ML was lower than that in group M but higher than that in group NC (normal), while the XOD activity in group MH was significantly reduced and more effective than that in group AP, showing great potential to replace positive control drugs. Figure 6H&E staining results showed that the HUA model caused liver and kidney damage in mice, and intervention in the ML and MH groups effectively improved the pathological features of the mice. In the NC normal group, hepatocytes had a round and dense morphology, large, round and centrally located nuclei, little heterochromatin and light staining, clearly visible nucleoli, and abundant hepatocyte cytoplasm. In the M model group, hepatocytes were swollen, with slight dilation of the sinusoids, irregular shape, inflammatory cell infiltration, and fat vesicle deposition. In the allopurinol group, compared with the model group, more dilated sinusoids, smaller hepatocyte volume and nuclei, and inflammatory cells (neutrophil infiltration) were observed in the lesions. Compared with the normal group, glomerular atrophy and deformation, significant tubular dilation, and mild renal edema were observed in the M model group and the AP allopurinol group. Allopurinol treatment aggravated renal edema and renal tubular damage, and these results are consistent with the nephrotoxicity of allopurinol. Significant improvement in these symptoms was observed in the ML and MH groups, therefore, the food-derived extract composition can alleviate symptoms of hyperuricemia and improve liver and kidney tissue damage.

[0069] Although embodiments of the invention have been disclosed for illustrative purposes, those skilled in the art will understand that various substitutions, variations, and modifications are possible without departing from the spirit and scope of the invention and the appended claims. Therefore, the scope of the invention is not limited to the contents disclosed in the embodiments.

Claims

1. A composition of a medicinal and edible extract, characterized in that: The composition of the medicinal and edible extracts is prepared from wolfberry, hawthorn, peppermint, winter melon peel and angelica dahurica; The extracts of wolfberry, hawthorn, peppermint, winter melon peel and angelica dahurica are prepared separately and scientifically compounded into a medicinal and edible extract composition. The preparation method of the medicinal and edible homologous extract is as follows: each raw material is crushed and passed through a 100-mesh sieve, and distilled water is added at a mass ratio of 1:

20. The mixture is decocted for 1 hour, filtered through double-layer gauze, and distilled water is added to the original weight. This process is repeated three times to obtain a liquid extract. The extract is then concentrated by rotary evaporation at 60°C in a water bath and 4°C in condensate for 2 hours. Finally, it is freeze-dried under vacuum to obtain freeze-dried powder of each medicinal and edible homologous extract. The composition of the medicinal and edible extracts consists of wolfberry extract, hawthorn extract, angelica dahurica extract, peppermint extract, and winter melon peel extract, with the following weight proportions for each ingredient: The total weight of the five ingredients is 100 parts: 10-30 parts of wolfberry extract, 1-10 parts of hawthorn extract, 1-10 parts of angelica dahurica extract, 30-60 parts of peppermint extract, and 30-60 parts of winter melon peel extract. Mix the above five extracts to obtain a composition of medicinal and edible extracts.

2. The composition of the medicinal and edible extract according to claim 1, characterized in that: The medicinal and edible extract composition has the ability to reduce serum uric acid and serum creatinine levels in hyperuricemia model animals, affect the expression levels of serum adenosine deaminase and xanthine oxidase, improve liver and kidney damage, and improve hyperuricemia.

3. The composition of the medicinal and edible extract according to claim 1 or 2, characterized in that: The composition of the medicinal and edible extracts has the ability to reduce serum uric acid and improve hyperuricemia in hyperuricemia model animals; Alternatively, the composition of the medicinal and edible extracts can reduce serum uric acid and creatinine levels in hyperuricemia model mice; Alternatively, the composition of the medicinal and edible extracts can effectively alleviate liver and kidney damage in hyperuricemia model mice and has a certain liver and kidney protection effect. Alternatively, the medicinal and edible extract composition can reduce serum uric acid and serum creatinine levels in hyperuricemia model animals, affect the expression levels of serum adenosine deaminase and xanthine oxidase, and improve hyperuricemia.

4. The use of the composition of the medicinal and edible extract as described in any one of claims 1 to 3 in the preparation of a medicament for relieving hyperuricemia and / or lowering uric acid.

5. The application according to claim 4, characterized in that: The composition of the medicinal and edible extracts in the drug is solid or liquid; Alternatively, the medicine may include a pharmaceutically acceptable carrier.

6. The application according to claim 4 or 5, characterized in that: The dosage form of the drug includes one or more oral preparations selected from tablets, capsules, oral liquids, or lyophilized preparations.

Images